Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts! Research/Science 8/20/2025
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
View this post in the Community →
Similar Community Posts Join
0 / 1 results — no results
Related Research
6 / 160 resultsresearch Immune and Non-Immune Interactions in the Pathogenesis of Androgenetic Alopecia
research Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
research Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
Damaging mutations in NFKB2 cause a severe and distinct form of primary immunodeficiency with early-onset and often ACTH-deficiency.
research The British Society for Rheumatology Guideline for the Management of Systemic Lupus Erythematosus in Adults
The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
research Scarless Wound Healing: Transitioning from Fetal Research to Regenerative Healing
Understanding how baby skin heals without scars could help develop treatments for adults to heal wounds without leaving scars.
research Regeneration of Dermis: Scarring and Cells Involved
Different fibroblasts play key roles in skin healing and scarring.